CBUS

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 6

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,936

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 5

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,826

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 4

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,026

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 3

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,920

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 2

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,120

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 1

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,320

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018.

SEC source: 0001615594-20-000007 · primary_doc.xml · nonDerivative · entry 1

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 11, 2019.

SEC source: 0001615594-20-000005 · primary_doc.xml · nonDerivative · entry 1

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100

F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 11, 2019.

SEC source: 0001615594-20-000004 · primary_doc.xml · nonDerivative · entry 2

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 825

F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 11, 2019.

F2 · price: The price reported in Column 4 is a weighted average. These shares were purchased in multiple transactions at prices ranging from $7.12 to $7.37, inclusive.

SEC source: 0001615594-20-000004 · primary_doc.xml · nonDerivative · entry 1

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550

F1 · kind: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 11, 2019.

SEC source: 0001615594-20-000003 · primary_doc.xml · nonDerivative · entry 1

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275

F1 · kind: The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 11, 2019.

SEC source: 0001615594-20-000002 · primary_doc.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,762

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

SEC source: 0001615594-20-000001 · primary_doc.xml · nonDerivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,655

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

SEC source: 0001615594-19-000036 · primary_doc.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,998

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

SEC source: 0001615594-19-000035 · primary_doc.xml · nonDerivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,900

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

SEC source: 0001615594-19-000030 · primary_doc.xml · nonDerivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,145

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

SEC source: 0001615594-19-000029 · primary_doc.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,234

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 20, 2017.

SEC source: 0001615594-21-000062 · primary_doc.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,354

F1 · shares: The sale reported on the Form 4 originally filed was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 30, 2017.

F2 · balance_after: The amount of securities beneficially owned by reporting person following the transaction was incorrectly stated.

SEC source: 0001615594-21-000059 · primary_doc.xml · nonDerivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,865

F1 · kind: The sale reported on the Form 4 originally filed was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on June 13, 2019.

F2 · balance_after: The number of shares beneficially owned by reporting person following the transaction reported on the Form 4 was incorrectly stated.

SEC source: 0001615594-19-000028 · primary_doc.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,323

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.58 to $12.80, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001615594-19-000025 · primary_doc.xml · derivative · entry 2

Koschak William · CIK 0001763989 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2022-06-28

F1 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

F1 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

SEC source: 0001615594-19-000026 · primary_doc.xml · derivative · entry 2

Frimerman Debra H · CIK 0001353541 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2022-06-28

F1 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon the increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

F1 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon the increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

SEC source: 0001615594-19-000027 · primary_doc.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,982

F1 · shares: 50,000 Restricted Stock Units with respect to Calyxt Inc. common stock were granted to reporting person on 6/28/2019 and vest as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning the first full quarter after the second anniversary of the Grant Date.

SEC source: 0001615594-19-000024 · primary_doc.xml · derivative · entry 3

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,667

Underlying: Common Stock · 166,667 shares

Expires 2022-06-28

F3 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

F3 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Calyxt common stock. The PSU will vest as to 50%, 100% or 120% of the shares at the end of a three year performance period based upon increases in Calyxt common stock from the starting price of $12.48 (and on a linear basis between vesting percentages) and if vested, will be issued as restricted stock with restrictions lapsing on the two year anniversary of the date of issuance.

SEC source: 0001615594-19-000024 · primary_doc.xml · derivative · entry 2

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2029-06-28

F2 · derivative.exercise_date: Stock Option vests as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning the first full calendar quarter after the second anniversary of the Grant Date.

SEC source: 0001615594-19-000024 · primary_doc.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,136

F1 · shares: 50,000 Restricted Stock Units with respect to Calyxt, Inc. common stock were granted to reporting person on 6/28/2019 and vest as to 15% of the underlying shares on the first anniversary of the Grant Date, as to 10% of the underlying shares on the second anniversary of the Grant Date, and as to 5% of the underlying shares on the last day of each calendar quarter beginning on the first full calendar quarter after the second anniversary of the Grant Date.

SEC source: 0001615594-19-000023 · primary_doc.xml · nonDerivative · entry 1

Choulika Andre · CIK 0001712190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,733

SEC source: 0001127602-19-019646 · form4.xml · derivative · entry 1

Frey Travis · CIK 0001777352 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The Stock Options were granted on May 20, 2019 and vest 15% on the first anniversary of the grant date and 10% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months (commencing on September 30, 2021).

SEC source: 0001127602-19-019054 · form4.xml · derivative · entry 1

Choulika Andre · CIK 0001712190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2029-05-15

F1 · derivative.exercise_date: The stock options to purchase shares of Calyxt, Inc. common stock ("Stock Options") were granted on May 15, 2019 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (commencing on September 30, 2021).

SEC source: 0001127602-19-018619 · form4.xml · derivative · entry 1

Frimerman Debra H · CIK 0001353541 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-05-13

F1 · derivative.exercise_date: The Stock Option was granted on May 13, 2019 and vests 15% on the first anniversary of the grant date and 10% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months (commencing on September 30, 2021).

SEC source: 0001127602-19-018609 · form4.xml · derivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2029-05-13

F1 · derivative.exercise_date: The Stock Option was granted on May 13, 2019 and vests 15% on the first anniversary of the grant date and 10% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months (commencing on September 30, 2021).

SEC source: 0001127602-19-018607 · form4.xml · derivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2029-05-13

F1 · derivative.exercise_date: The Stock Option was granted on May 13, 2019 and vests 15% on the first anniversary of the grant date and 10% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 45 months (commencing on September 30, 2021).

SEC source: 0001127602-19-017802 · form4.xml · derivative · entry 1

Nelson Kimberly K. · CIK 0001489097 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017806 · form4.xml · derivative · entry 1

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017805 · form4.xml · derivative · entry 1

Jonathan Fassberg · CIK 0001750985 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017804 · form4.xml · derivative · entry 1

NEUGENT CHRISTOPHER J · CIK 0001657549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017808 · form4.xml · derivative · entry 1

Choulika Andre · CIK 0001712190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017807 · form4.xml · derivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-017803 · form4.xml · derivative · entry 1

Kozicz-Stankiewicz Anna Ewa · CIK 0001712090 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2029-05-06

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-19-016564 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,611

Underlying: Common Stock · 3,750 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on April 7, 2016 and vested 20% on the grant date and 10% on April 7, 2017, with the remainder vesting quarterly in equal installments over the following 42 months, 25% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.

SEC source: 0001127602-19-016564 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.61, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-016564 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-014799 · form4.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,136

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 9, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.56 to $16.85, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 135,000 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on September 17, 2018 and remain unvested; 27,000 shares will vest on the October 1, 2019, and the remainder vesting quarterly (commencing with the fourth fiscal quarter of 2019) in equal installments over 36 months.

SEC source: 0001127602-19-013927 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,817

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.67, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 53,900 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 33 months.

SEC source: 0001127602-19-013430 · form4.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,718

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on September 17, 2018 and vested 25% on October 1, 2018, with 15% vesting on October 1, 2019, and the remainder vesting quarterly (commencing with the fourth fiscal quarter of 2019) in equal installments over 36 months.

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 9, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $18.09, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001127602-19-012652 · form4.xml · nonDerivative · entry 2

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,339

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 21, 2017.

F2 · balance_after: Includes 58,800 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 36 months.

SEC source: 0001127602-19-012485 · form4.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,300

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on September 17, 2018 and vested 25% on October 1, 2018, with 15% vesting on October 1, 2019, and the remainder vesting quarterly (commencing with the fourth fiscal quarter of 2019) in equal installments over 36 months.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.02 to $17.63, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001127602-19-012652 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,601

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 21, 2017.

F2 · balance_after: Includes 58,800 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 36 months.

SEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 4

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,020

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.82 to $16.85, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

SEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 3

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.76 to $16.365, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.